Investigators from Immunos Therapeutics AG aimed to develop novel anticancer therapies by using a reverse rational approach from HLA class I molecules with the aim to induce autoimmunity, and they identified HLA-B*57 as a well-known genetic factor associated with superior control of viral infections through processes not linked with peptide presentation.